Share

Pawlotsky, Jean-Michel fr

List of all publications

Publishing since 1992 (Senior)

    2010

  1. CommentJournal Article Pawlotsky JM, Chevaliez S. Preventing hepatitis C virus recurrence in liver transplant recipients: a role for adoptive immunotherapy?  Hepatology  2010;51;3  Link to Preventing hepatitis C virus recurrence in liver transplant recipients: a role for adoptive immunotherapy?
  2. Journal Article Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, Pohl RT, Pawlotsky JM. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.  Gastroenterology  2010;138;3  Link to Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
  3. Journal Article Monto A, Schooley RT, Lai JC, Sulkowski MS, Chung RT, Pawlotsky JM, McHutchison JG, Jacobson IM. Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop.  Am. J. Gastroenterol.  2010  Link to Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop.
  4. Congresses Pawlotsky JM, Cocquerel L, Durantel D, Lavillette D, Lerat H, Pécheur EI, Polyak SJ, Tautz N, Thimme R. HCV research 20 years after discovery: a summary of the 16th international symposium on hepatitis C virus and related viruses.  Gastroenterology  2010;138;1  Link to HCV research 20 years after discovery: a summary of the 16th international symposium on hepatitis C virus and related viruses.

    5. 2009

  5. Journal Article Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Norkrans G, Westin J, Söderholm J, Hellstrand K, Lagging M. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.  Hepatology  2009  Link to Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.
  6. Journal Article Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM, Heathcote EJ, Dusheiko G, Marcellin P. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report.  Liver Int.  2009  Link to The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report.
  7. Journal Article Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathurin P. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: A meta-analysis.  J. Hepatol.  2009  Link to Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: A meta-analysis.
  8. Journal Article Lukasiewicz E, Gorfine M, Freedman LS, Pawlotsky JM, Schalm SW, Ferrari C, Zeuzem S, Neumann AU. Prediction of nonSVR to therapy with pegylated interferon-alpha2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment.  J. Viral Hepat.  2009  Link to Prediction of nonSVR to therapy with pegylated interferon-alpha2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment.
  9. English AbstractJournal Article Pawlotsky JM. [The liver and Europe]  Gastroenterol. Clin. Biol.  2009;33;8-9  Link to [The liver and Europe]
  10. News Pawlotsky JM. Hepatitis: HCV variability, the immune system and resistance to antiviral drugs.  Nat Rev Gastroenterol Hepatol  2009;6;7  Link to Hepatitis: HCV variability, the immune system and resistance to antiviral drugs.
  11. Journal Article Morice Y, Ratinier M, Miladi A, Chevaliez S, Germanidis G, Wedemeyer H, Laperche S, Lavergne JP, Pawlotsky JM. Seroconversion to hepatitis C virus alternate reading frame protein during acute infection.  Hepatology  2009;49;5  Link to Seroconversion to hepatitis C virus alternate reading frame protein during acute infection.
  12. Clinical Trial, Phase IIComparative StudyJournal ArticleMulticenter StudyRandomized Controlled Trial Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.  N. Engl. J. Med.  2009;360;18  Link to Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
  13. Letter Chevaliez S, Bouvier-Alias M, Castéra L, Pawlotsky JM. The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples.  Hepatology  2009;49;4  Link to The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples.
  14. News Pawlotsky JM. EASL Clinical Practice Guidelines.  J. Hepatol.  2009;50;2  Link to EASL Clinical Practice Guidelines.
  15. Journal Article Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice.  PLoS ONE  2009;4;12  Link to Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice.
  16. Journal ArticleReview Chevaliez S, Pawlotsky JM. Virological techniques for the diagnosis and monitoring of hepatitis B and C.  Ann Hepatol  2009;8;1  Link to Virological techniques for the diagnosis and monitoring of hepatitis B and C.
  17. Journal ArticleReview Chevaliez S, Pawlotsky JM. How to use virological tools for optimal management of chronic hepatitis C.  Liver Int.  2009;29 Suppl 1  Link to How to use virological tools for optimal management of chronic hepatitis C.
  18. Journal ArticleRandomized Controlled Trial Pallier C, Rodriguez C, Brillet R, Nordmann P, Hézode C, Pawlotsky JM. Complex dynamics of hepatitis B virus resistance to adefovir.  Hepatology  2009;49;1  Link to Complex dynamics of hepatitis B virus resistance to adefovir.

    19. 2008

  19. Congresses Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F. Statements from the Taormina expert meeting on occult hepatitis B virus infection.  J. Hepatol.  2008;49;4  Link to Statements from the Taormina expert meeting on occult hepatitis B virus infection.
  20. Journal ArticleValidation Studies Challine D, Chevaliez S, Pawlotsky JM. Efficacy of serologic marker screening in identifying hepatitis B virus infection in organ, tissue, and cell donors.  Gastroenterology  2008;135;4  Link to Efficacy of serologic marker screening in identifying hepatitis B virus infection in organ, tissue, and cell donors.
  21. Case ReportsJournal Article Girou E, Chevaliez S, Challine D, Thiessart M, Morice Y, Lesprit P, Tkoub-Scheirlinck L, Soing-Altrach S, Cizeau F, Cavin C, André M, Dahmanne D, Lang P, Pawlotsky JM. Determinant roles of environmental contamination and noncompliance with standard precautions in the risk of hepatitis C virus transmission in a hemodialysis unit.  Clin. Infect. Dis.  2008;47;5  Link to Determinant roles of environmental contamination and noncompliance with standard precautions in the risk of hepatitis C virus transmission in a hemodialysis unit.
  22. In VitroJournal Article Piodi A, Chouteau P, Lerat H, Hézode C, Pawlotsky JM. Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis.  Hepatology  2008;48;1  Link to Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis.
  23. CommentLetter Germanidis G, Metallidis S, Lazaraki G, Pawlotsky JM, Nikolaidis P. NS5A sequences of hepatitis C virus genotype 1 and interferon resistance: where are we?  J. Infect. Dis.  2008;198;1  Link to NS5A sequences of hepatitis C virus genotype 1 and interferon resistance: where are we?
  24. Journal ArticleRandomized Controlled Trial Pugnale P, Herrmann E, Neumann AU, Pawlotsky JM, Schalm SW, Ferrari C, Homburger Y, Zeuzem S, Negro F. Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy.  J. Hepatol.  2008;48;6  Link to Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy.
  25. News Pawlotsky JM. Building a liver disease policy in the European Union.  J. Hepatol.  2008;48;6  Link to Building a liver disease policy in the European Union.
  26. Journal Article Ward CL, Dev A, Rigby S, Symonds WT, Patel K, Zekry A, Pawlotsky JM, McHutchison JG. Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase.  J. Viral Hepat.  2008  Link to Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase.
  27. Journal ArticleReview Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y. Chronic hepatitis B: preventing, detecting, and managing viral resistance.  Clin. Gastroenterol. Hepatol.  2008;6;3  Link to Chronic hepatitis B: preventing, detecting, and managing viral resistance.
  28. Journal ArticleResearch Support, N.I.H., ExtramuralResearch Support, N.I.H., IntramuralReview Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, Martin P, Richman DD, Zoulim F. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.  Gastroenterology  2008;134;2  Link to Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.
  29. Journal ArticleResearch Support, N.I.H., Extramural Smyk-Pearson S, Tester IA, Klarquist J, Palmer BE, Pawlotsky JM, Golden-Mason L, Rosen HR. Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help.  J. Virol.  2008;82;4  Link to Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help.
  30. Journal Article Westin J, Ydreborg M, Islam S, Alsiö A, Dhillon AP, Pawlotsky JM, Zeuzem S, Schalm SW, Ferrari C, Neumann AU, Hellstrand K, Lagging M. A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection.  Scand. J. Gastroenterol.  2008;43;1  Link to A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection.
  31. Journal ArticleReview Chevaliez S, Pawlotsky JM. Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes.  Best Pract Res Clin Gastroenterol  2008;22;6  Link to Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes.
  32. English AbstractJournal ArticleReview Pawlotsky JM. [Virologic techniques for the diagnosis and monitoring of hepatitis B]  Gastroenterol. Clin. Biol.  2008;32;1 Pt 2  Link to [Virologic techniques for the diagnosis and monitoring of hepatitis B]

    33. 2007

  33. Journal ArticleReview Chevaliez S, Pawlotsky JM. Practical use of hepatitis C virus kinetics monitoring in the treatment of chronic hepatitis C.  J. Viral Hepat.  2007;14 Suppl 1  Link to Practical use of hepatitis C virus kinetics monitoring in the treatment of chronic hepatitis C.
  34. Journal ArticleReview Chevaliez S, Pawlotsky JM. Interferon-based therapy of hepatitis C.  Adv. Drug Deliv. Rev.  2007;59;12  Link to Interferon-based therapy of hepatitis C.
  35. Clinical Trial, Phase IIIJournal ArticleMulticenter StudyRandomized Controlled Trial Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky JM, Zeuzem S, Schalm SW, von Wagner M, Germanidis G, Lurie Y, Esteban JI, Haagmans BL, Hezode C, Lagging M, Negro F, Homburger Y, Neumann AU, Ferrari C, Missale G. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).  Gastroenterology  2007;133;4  Link to HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).
  36. Consensus Development ConferenceJournal ArticlePractice Guideline de Araújo ES, Mendonça JS, Barone AA, Gonçales FL, Ferreira MS, Focaccia R, Pawlotsky JM. Consensus of the Brazilian Society of Infectious Diseases on the management and treatment of hepatitis C.  Braz J Infect Dis  2007;11;5  Link to Consensus of the Brazilian Society of Infectious Diseases on the management and treatment of hepatitis C.
  37. English AbstractJournal ArticleReview Marcellin P, Bourlière M, Pawlotsky JM, Ouzan D. [HCV non-responder patients: definition of non-response and treatment strategy]  Gastroenterol. Clin. Biol.  2007;31;8-9 Pt 3  Link to [HCV non-responder patients: definition of non-response and treatment strategy]
  38. Journal ArticleResearch Support, N.I.H., ExtramuralReview Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.  Hepatology  2007;46;1  Link to Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.
  39. Journal Article Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method.  Hepatology  2007;46;1  Link to Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method.
  40. Journal Article Chevaliez S, Brillet R, Lázaro E, Hézode C, Pawlotsky JM. Analysis of ribavirin mutagenicity in human hepatitis C virus infection.  J. Virol.  2007;81;14  Link to Analysis of ribavirin mutagenicity in human hepatitis C virus infection.
  41. Journal ArticleReview Chevaliez S, Pawlotsky JM. Hepatitis C virus: virology, diagnosis and management of antiviral therapy.  World J. Gastroenterol.  2007;13;17  Link to Hepatitis C virus: virology, diagnosis and management of antiviral therapy.
  42. CommentLetter Westin J, Hellstrand K, Alsiö A, Ydreborg M, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Verhey-Hart E, Lagging M. Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C.  Hepatology  2007;45;5  Link to Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C.
  43. Journal ArticleReview Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies.  Gastroenterology  2007;132;5  Link to The hepatitis C virus life cycle as a target for new antiviral therapies.
  44. Clinical TrialJournal Article Hézode C, Chevaliez S, Bouvier-Alias M, Roudot-Thoraval F, Brillet R, Zafrani ES, Dhumeaux D, Pawlotsky JM. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily.  J. Hepatol.  2007;46;5  Link to Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily.
  45. CommentEditorial Pawlotsky JM. Treatment of hepatitis C: don't put all your eggs in one basket!  Gastroenterology  2007;132;4  Link to Treatment of hepatitis C: don't put all your eggs in one basket!
  46. Comparative StudyJournal Article Brillet R, Penin F, Hezode C, Chouteau P, Dhumeaux D, Pawlotsky JM. The nonstructural 5A protein of hepatitis C virus genotype 1b does not contain an interferon sensitivity-determining region.  J. Infect. Dis.  2007;195;3  Link to The nonstructural 5A protein of hepatitis C virus genotype 1b does not contain an interferon sensitivity-determining region.
  47. Clinical Trial, Phase IIIJournal ArticleMulticenter StudyRandomized Controlled Trial Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, Pawlotsky JM, Zeuzem S, Schalm SW, Verheij-Hart E, Negro F, Missale G, Neumann AU, Hellstrand K. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.  J. Viral Hepat.  2007;14;1  Link to Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
  48. CommentLetter Lukasiewicz E, Hellstrand K, Westin J, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Veldt BJ, Hansen BE, Verhey-Hart E, Lagging M. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.  Hepatology  2007;45;1  Link to Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.

    49. 2006

  49. Journal ArticleMulticenter StudyRandomized Controlled Trial Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, Zeuzem S, von Wagner M, Negro F, Schalm SW, Haagmans BL, Ferrari C, Missale G, Neumann AU, Verheij-Hart E, Hellstrand K. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection.  Hepatology  2006;44;6  Link to IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection.
  50. Journal ArticleResearch Support, N.I.H., Extramural Kuiken C, Combet C, Bukh J, Shin-I T, Deleage G, Mizokami M, Richardson R, Sablon E, Yusim K, Pawlotsky JM, Simmonds P. A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes.  Hepatology  2006;44;5  Link to A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes.
  51. Clinical Trial, Phase IIIJournal ArticleMulticenter StudyRandomized Controlled Trial Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM, Neumann AU, Ferrari C, Missale G, Haagmans BL, Schalm SW, Zeuzem S, Negro F, Verheij-Hart E, Hellstrand K. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.  J. Infect. Dis.  2006;194;7  Link to Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
  52. Journal ArticleMulticenter StudyRandomized Controlled Trial Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourlière M, Renou C, Tran A, Melin P, Hézode C, Chevalier M, Bouvier-Alias M, Chevaliez S, Montestruc F, Lonjon-Domanec I, Pawlotsky JM. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.  Gastroenterology  2006;131;4  Link to Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
  53. Journal ArticleResearch Support, N.I.H., Extramural Morice Y, Cantaloube JF, Beaucourt S, Barbotte L, De Gendt S, Goncales FL, Butterworth L, Cooksley G, Gish RG, Beaugrand M, Fay F, Fay O, Gonzalez JE, Martins RM, Dhumeaux D, Vanderborght B, Stuyver L, Sablon E, de Lamballerie X, Pawlotsky JM. Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users.  J. Med. Virol.  2006;78;10  Link to Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users.
  54. Comparative StudyJournal Article Challine D, Roudot-Thoraval F, Sabatier P, Dubernet F, Larderie P, Rigot P, Pawlotsky JM. Serological viral testing of cadaveric cornea donors.  Transplantation  2006;82;6  Link to Serological viral testing of cadaveric cornea donors.
  55. News Pawlotsky JM. Science, medicine and... the markets.  J. Hepatol.  2006;45;3  Link to Science, medicine and... the markets.
  56. EditorialReview Pawlotsky JM. [New therapeutic strategies in chronic hepatitis C]  Gastroenterol. Clin. Biol.  2006;30;8-9  Link to [New therapeutic strategies in chronic hepatitis C]
  57. Journal ArticleReview McHutchison JG, Bartenschlager R, Patel K, Pawlotsky JM. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.  J. Hepatol.  2006;44;2  Link to The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.
  58. Journal ArticleReview Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication.  Hepatology  2006;43;2 Suppl 1  Link to Therapy of hepatitis C: from empiricism to eradication.
  59. Journal ArticleReview Pawlotsky JM, Gish RG. Future therapies for hepatitis C.  Antivir. Ther. (Lond.)  2006;11;4  Link to Future therapies for hepatitis C.
  60. Journal Article Chevaliez S, Pawlotsky JM. Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease.  Int J Med Sci  2006;3;2  Link to Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease.
  61. Journal Article Pallier C, Castéra L, Soulier A, Hézode C, Nordmann P, Dhumeaux D, Pawlotsky JM. Dynamics of hepatitis B virus resistance to lamivudine.  J. Virol.  2006;80;2  Link to Dynamics of hepatitis B virus resistance to lamivudine.
  62. Journal ArticleReview Pawlotsky JM. Virology of hepatitis B and C viruses and antiviral targets.  J. Hepatol.  2006;44;1 Suppl  Link to Virology of hepatitis B and C viruses and antiviral targets.

    63. 2005

  63. Journal ArticleReview Pawlotsky JM. The concept of hepatitis B virus mutant escape.  J. Clin. Virol.  2005;34 Suppl 1  Link to The concept of hepatitis B virus mutant escape.
  64. Journal Article Callens N, Ciczora Y, Bartosch B, Vu-Dac N, Cosset FL, Pawlotsky JM, Penin F, Dubuisson J. Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry.  J. Virol.  2005;79;24  Link to Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry.
  65. Consensus Development ConferenceJournal ArticleReview Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.  Hepatology  2005;42;4  Link to Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.
  66. Journal Article Terrault NA, Pawlotsky JM, McHutchison J, Anderson F, Krajden M, Gordon S, Zitron I, Perrillo R, Gish R, Holodniy M, Friesenhahn M. Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy.  J. Viral Hepat.  2005;12;5  Link to Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy.
  67. Clinical TrialClinical Trial, Phase IIIJournal ArticleMulticenter StudyRandomized Controlled Trial Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, Gianfranco E, Vrolijk JM, Esteban JI, Hezode C, Lagging M, Negro F, Soulier A, Verheij-Hart E, Hansen B, Tal R, Ferrari C, Schalm SW, Neumann AU. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.  J. Hepatol.  2005;43;2  Link to International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.
  68. Journal ArticleReview Chevaliez S, Pawlotsky JM. Use of virologic assays in the diagnosis and management of hepatitis C virus infection.  Clin Liver Dis  2005;9;3  Link to Use of virologic assays in the diagnosis and management of hepatitis C virus infection.
  69. Journal ArticleMulticenter Study Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, Trimoulet P, Couzigou P, Cointe D, Chaput C, Henquell C, Abergel A, Pawlotsky JM, Hezode C, Coudé M, Blanchi A, Alain S, Loustaud-Ratti V, Chevallier P, Trepo C, Gerolami V, Portal I, Halfon P, Bourlière M, Bogard M, Plouvier E, Laffont C, Agius G, Silvain C, Brodard V, Thiefin G, Buffet-Janvresse C, Riachi G, Grattard F, Bourlet T, Stoll-Keller F, Doffoel M, Izopet J, Barange K, Martinot-Peignoux M, Branger M, Rosenberg A, Sogni P, Chaix ML, Pol S, Thibault V, Opolon P, Charrois A, Serfaty L, Fouqueray B, Grange JD, Lefrère JJ, Lunel-Fabiani F. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study.  J. Viral Hepat.  2005;12;4  Link to Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study.
  70. Journal ArticleReview Adler M, Goubau P, Leroux-Roels G, Sprengers D, Pawlotsky JM. Practical use of hepatitis C and B molecular tools: Belgian guidelines.  Acta Gastroenterol. Belg.  2005;68;3  Link to Practical use of hepatitis C and B molecular tools: Belgian guidelines.
  71. Journal Article Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlotsky JM, Lavillette D, Cosset FL. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies.  J. Virol.  2005;79;13  Link to An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies.
  72. Journal Article Hézode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, Pawlotsky JM, Pawlostky JM, Dhumeaux D, Lotersztajn S, Mallat A. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.  Hepatology  2005;42;1  Link to Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.
  73. Comparative StudyJournal Article Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E, Sakellariou G, Intrator L, Bartosch B, Pawlotsky JM, Cosset FL. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection.  J. Virol.  2005;79;10  Link to Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection.
  74. English AbstractJournal ArticleReview Chevaliez S, Pawlotsky JM. [Screening and diagnosis of hepatitis B and C]  Rev Prat  2005;55;6  Link to [Screening and diagnosis of hepatitis B and C]
  75. Journal ArticleReview Castera L, Chouteau P, Hezode C, Zafrani ES, Dhumeaux D, Pawlotsky JM. Hepatitis C virus-induced hepatocellular steatosis.  Am. J. Gastroenterol.  2005;100;3  Link to Hepatitis C virus-induced hepatocellular steatosis.
  76. Journal ArticleReview Pawlotsky JM. Current and future concepts in hepatitis C therapy.  Semin. Liver Dis.  2005;25;1  Link to Current and future concepts in hepatitis C therapy.
  77. Journal ArticleReview Castera L, Pawlotsky JM. Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C.  MedGenMed  2005;7;4  Link to Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C.

    78. 2004

  78. Clinical TrialClinical Trial, Phase IJournal Article Soler M, McHutchison JG, Kwoh TJ, Dorr FA, Pawlotsky JM. Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment.  Antivir. Ther. (Lond.)  2004;9;6  Link to Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment.
  79. Evaluation StudiesJournal ArticleResearch Support, U.S. Gov't, P.H.S.Validation Studies Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, Pawlotsky JM, McHutchison JG. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients.  J. Hepatol.  2004;41;6  Link to Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients.
  80. CommentEditorial Pawlotsky JM. Hepatitis C: it's a long way to new therapy, it's a long way to go...  Gastroenterology  2004;127;5  Link to Hepatitis C: it's a long way to new therapy, it's a long way to go...
  81. Journal ArticleReview Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, Pawlotsky JM, Zoulim F. Management of antiviral resistance in patients with chronic hepatitis B.  Antivir. Ther. (Lond.)  2004;9;5  Link to Management of antiviral resistance in patients with chronic hepatitis B.
  82. Journal Article Challine D, Pellegrin B, Bouvier-Alias M, Rigot P, Laperche L, Pawlotsky JM. HIV and hepatitis C virus RNA in seronegative organ and tissue donors.  Lancet  2004;364;9445  Link to HIV and hepatitis C virus RNA in seronegative organ and tissue donors.
  83. Journal Article Hézode C, Roudot-Thoraval F, Zafrani ES, Dhumeaux D, Pawlotsky JM. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections.  J. Viral Hepat.  2004;11;5  Link to Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections.
  84. CommentJournal Article Pawlotsky JM. Treating hepatitis C in "difficult-to-treat" patients.  N. Engl. J. Med.  2004;351;5  Link to Treating hepatitis C in "difficult-to-treat" patients.
  85. Journal ArticleResearch Support, U.S. Gov't, P.H.S. Prince AM, Pawlotsky JM, Soulier A, Tobler L, Brotman B, Pfahler W, Lee DH, Li L, Shata MT. Hepatitis C virus replication kinetics in chimpanzees with self-limited and chronic infections.  J. Viral Hepat.  2004;11;3  Link to Hepatitis C virus replication kinetics in chimpanzees with self-limited and chronic infections.
  86. Journal Article Pellerin M, Lopez-Aguirre Y, Penin F, Dhumeaux D, Pawlotsky JM. Hepatitis C virus quasispecies variability modulates nonstructural protein 5A transcriptional activation, pointing to cellular compartmentalization of virus-host interactions.  J. Virol.  2004;78;9  Link to Hepatitis C virus quasispecies variability modulates nonstructural protein 5A transcriptional activation, pointing to cellular compartmentalization of virus-host interactions.
  87. Journal Article Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, Castera L, Dhumeaux D. Antiviral action of ribavirin in chronic hepatitis C.  Gastroenterology  2004;126;3  Link to Antiviral action of ribavirin in chronic hepatitis C.
  88. Journal Article Castéra L, Hézode C, Roudot-Thoraval F, Lonjon I, Zafrani ES, Pawlotsky JM, Dhumeaux D. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis.  Gut  2004;53;3  Link to Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis.
  89. Consensus Development ConferenceJournal ArticleReview Pawlotsky JM, McHutchison JG. Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003.  Hepatology  2004;39;2  Link to Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003.
  90. Journal ArticleReview Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus.  Hepatology  2004;39;1  Link to Structural biology of hepatitis C virus.

    91. 2003

  91. Journal ArticleReview Hezode C, Castera L, Chouteau P, Dhumeaux D, Pawlotsky JM. [Steasis and hepatitis C]  Gastroenterol. Clin. Biol.  2003;27;12  Link to [Steasis and hepatitis C]
  92. Journal ArticleReview Pawlotsky JM. The nature of interferon-alpha resistance in hepatitis C virus infection.  Curr. Opin. Infect. Dis.  2003;16;6  Link to The nature of interferon-alpha resistance in hepatitis C virus infection.
  93. CommentLetter Castéra L, Pawlotsky JM, Dhumeaux D. Worsening of steatosis and fibrosis progression in hepatitis C.  Gut  2003;52;10  Link to Worsening of steatosis and fibrosis progression in hepatitis C.
  94. Journal ArticleReview Pawlotsky JM. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C.  Antiviral Res.  2003;59;1  Link to Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C.
  95. Journal Article Hézode C, Lonjon I, Roudot-Thoraval F, Pawlotsky JM, Zafrani ES, Dhumeaux D. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study.  Aliment. Pharmacol. Ther.  2003;17;8  Link to Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study.
  96. Journal ArticleReview Pawlotsky JM. Use and interpretation of hepatitis C virus diagnostic assays.  Clin Liver Dis  2003;7;1  Link to Use and interpretation of hepatitis C virus diagnostic assays.
  97. Journal ArticleReview Pawlotsky JM. Hepatitis C virus genetic variability: pathogenic and clinical implications.  Clin Liver Dis  2003;7;1  Link to Hepatitis C virus genetic variability: pathogenic and clinical implications.
  98. Journal Article Castéra L, Hézode C, Roudot-Thoraval F, Bastie A, Zafrani ES, Pawlotsky JM, Dhumeaux D. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.  Gut  2003;52;2  Link to Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.
  99. Journal ArticleReview Pawlotsky JM. Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics.  J. Hepatol.  2003;39 Suppl 1  Link to Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics.
  100. Journal ArticleReview Pawlotsky JM. Diagnostic testing in hepatitis C virus infection: viral kinetics and genomics.  Semin. Liver Dis.  2003;23 Suppl 1  Link to Diagnostic testing in hepatitis C virus infection: viral kinetics and genomics.
  101. Journal Article Hézode C, Lonjon I, Roudot-Thoraval F, Mavier JP, Pawlotsky JM, Zafrani ES, Dhumeaux D. Impact of smoking on histological liver lesions in chronic hepatitis C.  Gut  2003;52;1  Link to Impact of smoking on histological liver lesions in chronic hepatitis C.

    102. 2002

  102. Journal ArticleReview Pawlotsky JM. Use and interpretation of virological tests for hepatitis C.  Hepatology  2002;36;5 Suppl 1  Link to Use and interpretation of virological tests for hepatitis C.
  103. In VitroJournal Article Castet V, Fournier C, Soulier A, Brillet R, Coste J, Larrey D, Dhumeaux D, Maurel P, Pawlotsky JM. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro.  J. Virol.  2002;76;16  Link to Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro.
  104. Journal Article Challine D, Buisson M, Cadilhac M, Germanidis G, Joab I, Eliaszewicz M, Caumes E, Flahault A, Fillet AM, Pawlotsky JM, Seigneurin JM. Hepatitis C virus-Epstein-Barr virus interaction in patients with AIDS.  J. Med. Virol.  2002;67;4  Link to Hepatitis C virus-Epstein-Barr virus interaction in patients with AIDS.
  105. Journal Article Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, Blatt L, Hezode C, Picchio G, Dhumeaux D, Neumann AU, McHutchison JG, Pawlotsky JM. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.  Hepatology  2002;36;1  Link to Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.
  106. Comparative StudyJournal Article Soler M, Pellerin M, Malnou CE, Dhumeaux D, Kean KM, Pawlotsky JM. Quasispecies heterogeneity and constraints on the evolution of the 5' noncoding region of hepatitis C virus (HCV): relationship with HCV resistance to interferon-alpha therapy.  Virology  2002;298;1  Link to Quasispecies heterogeneity and constraints on the evolution of the 5' noncoding region of hepatitis C virus (HCV): relationship with HCV resistance to interferon-alpha therapy.
  107. Journal ArticleReview Pawlotsky JM. Molecular diagnosis of viral hepatitis.  Gastroenterology  2002;122;6  Link to Molecular diagnosis of viral hepatitis.
  108. Comparative StudyConsensus Development ConferenceJournal ArticleReview Pawlotsky JM. [Management of patients with hepatitis C virus infection. Virological tests]  Gastroenterol. Clin. Biol.  2002;26 Spec No 2  Link to [Management of patients with hepatitis C virus infection. Virological tests]
  109. Journal Article Quadri R, Giostra E, Roskams T, Pawlotsky JM, Mentha G, Rubbia-Brandt L, Perrin L, Hadengue A, Negro F. Immunological and virological effects of ribavirin in hepatitis C after liver transplantation.  Transplantation  2002;73;3  Link to Immunological and virological effects of ribavirin in hepatitis C after liver transplantation.
  110. Comparative StudyJournal Article Duvoux C, Tran Ngoc A, Intrator L, Hézode C, Germanidis G, Pawlotsky JM, Cherqui D, Dhumeaux D. Hepatitis C virus (HCV)-related cryoglobulinemia after liver transplantation for HCV cirrhosis.  Transpl. Int.  2002;15;1  Link to Hepatitis C virus (HCV)-related cryoglobulinemia after liver transplantation for HCV cirrhosis.

    111. 2001

  111. Journal Article Challine D, Roudot-Thoraval F, Sarah T, Laperche L, Boisson B, Mauberquez S, Dubernet F, Rigot P, Lefrère F, Mercier B, Brossard Y, Rouet F, Girot R, Loiseau P, Girard D, Claquin J, Loty B, Lerable J, Mariotti M, Pawlotsky JM, Lefrère JJ. Seroprevalence of human herpes virus 8 antibody in populations at high or low risk of transfusion, graft, or sexual transmission of viruses.  Transfusion  2001;41;9  Link to Seroprevalence of human herpes virus 8 antibody in populations at high or low risk of transfusion, graft, or sexual transmission of viruses.
  112. Journal Article Castera L, Dhumeaux D, Pawlotsky JM. [Chronic viral hepatitis B and C. Epidemiology, diagnosis, etiology, prevention]  Rev Prat  2001;51;11  Link to [Chronic viral hepatitis B and C. Epidemiology, diagnosis, etiology, prevention]
  113. Journal Article Penin F, Combet C, Germanidis G, Frainais PO, Deléage G, Pawlotsky JM. Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment.  J. Virol.  2001;75;12  Link to Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment.
  114. Journal ArticleReview Castera L, Pawlotsky JM. [Hepatitis E virus infection: epidemiology and prevention]  Gastroenterol. Clin. Biol.  2001;25;5  Link to [Hepatitis E virus infection: epidemiology and prevention]
  115. Journal ArticleReview Pawlotsky JM. [Hepatitis C virus and immune response]  Gastroenterol. Clin. Biol.  2001;25;4 Suppl  Link to [Hepatitis C virus and immune response]
  116. Journal Article Castera L, Pawlotsky JM. [Can the outcome of acute hepatitis C be predicted by early changes in viral quasispecies?]  Gastroenterol. Clin. Biol.  2001;25;2  Link to [Can the outcome of acute hepatitis C be predicted by early changes in viral quasispecies?]

    117. 2000

  117. Journal ArticleReview Pawlotsky JM. Hepatitis C virus resistance to antiviral therapy.  Hepatology  2000;32;5  Link to Hepatitis C virus resistance to antiviral therapy.
  118. Comparative StudyJournal Article Laporte J, Malet I, Andrieu T, Thibault V, Toulme JJ, Wychowski C, Pawlotsky JM, Huraux JM, Agut H, Cahour A. Comparative analysis of translation efficiencies of hepatitis C virus 5' untranslated regions among intraindividual quasispecies present in chronic infection: opposite behaviors depending on cell type.  J. Virol.  2000;74;22  Link to Comparative analysis of translation efficiencies of hepatitis C virus 5' untranslated regions among intraindividual quasispecies present in chronic infection: opposite behaviors depending on cell type.
  119. Clinical TrialJournal Article Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification.  Hepatology  2000;32;3  Link to Standardization of hepatitis C virus RNA quantification.
  120. CongressesReview Pawlotsky JM. Hepatitis C: virology, clinical aspects and the relation to cryoglobulinemia.  Acta Gastroenterol. Belg.  2000;63;2  Link to Hepatitis C: virology, clinical aspects and the relation to cryoglobulinemia.
  121. Journal ArticleMulticenter Study Lefrère JJ, Lerable J, Mariotti M, Bogard M, Thibault V, Frangeul L, Loiseau P, Bouchardeau F, Laperche S, Pawlotsky JM, Cantaloube JF, Biagini P, de Lamballerie X, Izopet J, Defer C, Lepot I, Poveda JD, Dussaix E, Gerolami V, Halfon P, Buffet-Janvresse C, Férec C, Mercier B, Marcellin P, Martinot-Peignoux M, Gassain M. Lessons from a multicentre study of the detectability of viral genomes based on a two-round quality control of GB virus C (GBV-C)/hepatitis G virus (HGV) polymerase chain reaction assay.  J. Virol. Methods  2000;85;1-2  Link to Lessons from a multicentre study of the detectability of viral genomes based on a two-round quality control of GB virus C (GBV-C)/hepatitis G virus (HGV) polymerase chain reaction assay.
  122. Comparative StudyJournal Article Pawlotsky JM, Bastie A, Hézode C, Lonjon I, Darthuy F, Rémiré J, Dhumeaux D. Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays.  J. Virol. Methods  2000;85;1-2  Link to Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays.
  123. Clinical TrialCommentLetterRandomized Controlled Trial Bastie A, Castera L, Roudot-Thoraval F, Dhumeaux D, Pawlotsky JM. Inhibition of the cyclooxygenase/lipoxygenase pathways to improve interferon alfa efficacy in chronic hepatitis C: a wrong track.  Hepatology  2000;31;2  Link to Inhibition of the cyclooxygenase/lipoxygenase pathways to improve interferon alfa efficacy in chronic hepatitis C: a wrong track.

    124. 1999

  124. Journal Article Hézode C, Cazeneuve C, Coué O, Roudot-Thoraval F, Lonjon I, Bastie A, Duvoux C, Pawlotsky JM, Zafrani ES, Amselem S, Dhumeaux D. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions.  J. Hepatol.  1999;31;6  Link to Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions.
  125. English AbstractJournal Article Pawlotsky JM, Dhumeaux D. [The G virus: the orphan virus]  Presse Med  1999;28;34  Link to [The G virus: the orphan virus]
  126. Journal Article Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, Coste J, Izopet J, Duverlie G, Payan C, Pawlotsky JM, Defer C, Bogard M, Gerolami V, Halfon P, Buisson Y, Fouqueray B, Loiseau P, Lamoril J, Lefrere JJ, Marcellin P. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP.  J. Viral Hepat.  1999;6;6  Link to Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP.
  127. Journal Article Duvoux C, Pawlotsky JM, Bastie A, Cherqui D, Soussy CJ, Dhumeaux D. Low HCV replication levels in end-stage hepatitis C virus-related liver disease.  J. Hepatol.  1999;31;4  Link to Low HCV replication levels in end-stage hepatitis C virus-related liver disease.
  128. Journal ArticleReview Pawlotsky JM, Germanidis G. The non-structural 5A protein of hepatitis C virus.  J. Viral Hepat.  1999;6;5  Link to The non-structural 5A protein of hepatitis C virus.
  129. CommentLetter Germanidis G, haioun C, Dhumeaux D, Reyes F, Pawlotsky JM. Hepatitis C virus infection, mixed cryoglobulinemia, and B-cell non-Hodgkin's lymphoma.  Hepatology  1999;30;3  Link to Hepatitis C virus infection, mixed cryoglobulinemia, and B-cell non-Hodgkin's lymphoma.
  130. Journal Article Hézode C, Duvoux C, Germanidis G, Roudot-Thoraval F, Vincens AL, Gaulard P, Cherqui D, Pawlotsky JM, Dhumeaux D. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation.  Hepatology  1999;30;3  Link to Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation.
  131. Journal Article Pawlotsky JM, Germanidis G, Frainais PO, Bouvier M, Soulier A, Pellerin M, Dhumeaux D. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy.  J. Virol.  1999;73;8  Link to Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy.
  132. Journal Article Pawlotsky JM. Hepatitis C virus (HCV) NS5A protein: role in HCV replication and resistance to interferon-alpha.  J. Viral Hepat.  1999;6 Suppl 1  Link to Hepatitis C virus (HCV) NS5A protein: role in HCV replication and resistance to interferon-alpha.
  133. Journal ArticleReview Castera L, Dhumeaux D, Pawlotsky JM. [The role of virologic tests in the treatment of chronic hepatitis C]  Gastroenterol. Clin. Biol.  1999;23;6-7  Link to [The role of virologic tests in the treatment of chronic hepatitis C]
  134. Journal ArticleMulticenter Study Lefrère JJ, Cantaloube JF, Defer C, Mercier B, Loiseau P, Vignon D, Pawlotsky JM, Biagini P, Lerable J, Rouger P, Roudot-Thoraval F, Férec C. Screening for HBV, HCV and HIV genomes in blood donations: shortcomings of pooling revealed by a multicentre study simulating real-time testing.  J. Virol. Methods  1999;80;1  Link to Screening for HBV, HCV and HIV genomes in blood donations: shortcomings of pooling revealed by a multicentre study simulating real-time testing.
  135. Comparative StudyJournal Article Pawlotsky JM, Martinot-Peignoux M, Poveda JD, Bastie A, Le Breton V, Darthuy F, Rémiré J, Erlinger S, Dhumeaux D, Marcellin P. Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays.  J. Virol. Methods  1999;79;2  Link to Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays.
  136. CommentLetter Hézode C, Cazeneuve C, Coué O, Roudot-Thoraval F, Pawlotsky JM, Zafrani ES, Amslem S, Dhumeaux D. Hemochromatosis C282Y mutation and histological fibrosis in patients with C virus chronic hepatitis.  Hepatology  1999;29;4  Link to Hemochromatosis C282Y mutation and histological fibrosis in patients with C virus chronic hepatitis.
  137. English AbstractJournal Article Faulques B, Michault A, Sevidjian B, Barau G, Pawlotsky JM, Dhumeaux D. [Prevalence of hepatitis C virus infection in pregnant woman on the island of Réunion]  Gastroenterol. Clin. Biol.  1999;23;3  Link to [Prevalence of hepatitis C virus infection in pregnant woman on the island of Réunion]
  138. Letter Germanidis G, Haioun C, Pourquier J, Gaulard P, Pawlotsky JM, Dhumeaux D, Reyes F. Hepatitis C virus infection in patients with overt B-cell non-Hodgkin's lymphoma in a French center.  Blood  1999;93;5  Link to Hepatitis C virus infection in patients with overt B-cell non-Hodgkin's lymphoma in a French center.
  139. Journal ArticleReview Pawlotsky JM. Diagnostic tests for hepatitis C.  J. Hepatol.  1999;31 Suppl 1  Link to Diagnostic tests for hepatitis C.

    140. 1998

  140. Journal Article Lefrère JJ, Coste J, Defer C, Mercier B, Férec C, Loiseau P, Portelette E, Mariotti M, Lerable J, Rouger P, Pawlotsky JM. Screening blood donations for viral genomes: multicenter study of real-time simulation using pooled samples on the model of hepatitis C virus RNA detection.  Transfusion  1998;38;10  Link to Screening blood donations for viral genomes: multicenter study of real-time simulation using pooled samples on the model of hepatitis C virus RNA detection.
  141. Journal ArticleReview Pawlotsky JM. Hepatitis C virus infection: virus/host interactions.  J. Viral Hepat.  1998;5 Suppl 1  Link to Hepatitis C virus infection: virus/host interactions.
  142. Journal Article Pawlotsky JM, Lonjon I, Hezode C, Raynard B, Darthuy F, Remire J, Soussy CJ, Dhumeaux D. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories?  Hepatology  1998;27;6  Link to What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories?
  143. Journal ArticleReview Pawlotsky JM. Genetic heterogeneity and properties of hepatitis C virus.  Acta Gastroenterol. Belg.  1998;61;2  Link to Genetic heterogeneity and properties of hepatitis C virus.
  144. Journal Article Pawlotsky JM, Pellerin M, Bouvier M, Roudot-Thoraval F, Germanidis G, Bastie A, Darthuy F, Rémiré J, Soussy CJ, Dhumeaux D. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.  J. Med. Virol.  1998;54;4  Link to Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
  145. Journal Article Pawlotsky JM, Germanidis G, Neumann AU, Pellerin M, Frainais PO, Dhumeaux D. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations.  J. Virol.  1998;72;4  Link to Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations.
  146. Journal Article Lamoril J, Andant C, Bogard C, Puy H, Gouya L, Pawlotsky JM, Da Silva V, Soulé JC, Deybach JC, Nordmann Y. Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda.  Hepatology  1998;27;3  Link to Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda.
  147. Journal ArticleReview Pawlotsky JM, Gretch DR. Molecular tools for the treatment of hepatitis C.  Antivir. Ther. (Lond.)  1998;3;Suppl 3  Link to Molecular tools for the treatment of hepatitis C.
  148. Journal Article Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, Tran van Nhieu J, Seigneurin JM, Buffet C, Dhumeaux D. Characteristics of patients with dual infection by hepatitis B and C viruses.  J. Hepatol.  1998;28;1  Link to Characteristics of patients with dual infection by hepatitis B and C viruses.
  149. Letter Tkoub EM, Haioun C, Pawlotsky JM, Dhumeaux D, Delchier JC. Chronic hepatitis C virus and gastric MALT lymphoma.  Blood  1998;91;1  Link to Chronic hepatitis C virus and gastric MALT lymphoma.
  150. Journal Article Pawlotsky JM, Roudot-Thoraval F, Muerhoff AS, Pellerin M, Germanidis G, Desai SM, Bastie A, Darthuy F, Rémiré J, Zafrani ES, Soussy CJ, Mushahwar IK, Dhumeaux D. GB virus C (GBV-C) infection in patients with chronic hepatitis C. Influence on liver disease and on hepatitis virus behaviour: effect of interferon alfa therapy.  J. Med. Virol.  1998;54;1  Link to GB virus C (GBV-C) infection in patients with chronic hepatitis C. Influence on liver disease and on hepatitis virus behaviour: effect of interferon alfa therapy.
  151. CommentLetter Hezode C, Cazeneuve C, Coué O, Pawlotsky JM, Zafrani ES, Amselem S, Dhumeaux D. Hemochromatosis Cys282Tyr mutation and liver iron overload in patients with chronic active hepatitis C.  Hepatology  1998;27;1  Link to Hemochromatosis Cys282Tyr mutation and liver iron overload in patients with chronic active hepatitis C.

    152. 1997

  152. Comparative StudyJournal Article Prescott LE, Berger A, Pawlotsky JM, Conjeevaram P, Pike I, Simmonds P. Sequence analysis of hepatitis C virus variants producing discrepant results with two different genotyping assays.  J. Med. Virol.  1997;53;3  Link to Sequence analysis of hepatitis C virus variants producing discrepant results with two different genotyping assays.
  153. CommentEditorial Pawlotsky JM. Chronic hepatitis C virus infection with repeatedly normal aminotransferase levels: disease or not disease?  Am. J. Gastroenterol.  1997;92;10  Link to Chronic hepatitis C virus infection with repeatedly normal aminotransferase levels: disease or not disease?
  154. Journal Article Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus.  Hepatology  1997;26;2  Link to Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus.
  155. Journal ArticleReview Pawlotsky JM. Measuring hepatitis C viremia in clinical samples: can we trust the assays?  Hepatology  1997;26;1  Link to Measuring hepatitis C viremia in clinical samples: can we trust the assays?
  156. Comparative StudyJournal Article Pawlotsky JM, Bastie A, Lonjon I, Rémiré J, Darthuy F, Soussy CJ, Dhumeaux D. What technique should be used for routine detection and quantification of HBV DNA in clinical samples?  J. Virol. Methods  1997;65;2  Link to What technique should be used for routine detection and quantification of HBV DNA in clinical samples?
  157. Journal ArticleReview Pawlotsky JM. [Should hepatitis C be treated? Which biological tests are useful before deciding or refuting a treatment with interferon-alpha in patients with chronic hepatitis C?]  Gastroenterol. Clin. Biol.  1997;21;1 Pt 2  Link to [Should hepatitis C be treated? Which biological tests are useful before deciding or refuting a treatment with interferon-alpha in patients with chronic hepatitis C?]
  158. Journal Article Bralet MP, Roudot-Thoraval F, Pawlotsky JM, Bastie A, Tran Van Nhieu J, Duval J, Dhumeaux D, Zafrani ES. Histopathologic impact of GB virus C infection on chronic hepatitis C.  Gastroenterology  1997;112;1  Link to Histopathologic impact of GB virus C infection on chronic hepatitis C.

    159. 1996

  159. Journal Article Duvoux C, Pawlotsky JM, Cherqui D, Métreau JM, Fagniez PL, Duval J, Dhumeaux D. Initial clinical patterns of hepatitis C virus reinfection after liver transplantation for hepatitis C virus-related cirrhosis.  Transplant. Proc.  1996;28;5  Link to Initial clinical patterns of hepatitis C virus reinfection after liver transplantation for hepatitis C virus-related cirrhosis.
  160. Journal Article Pawlotsky JM, Roudot-Thoraval F, Bastie A, Darthuy F, Rémiré J, Métreau JM, Zafrani ES, Duval J, Dhumeaux D. Factors affecting treatment responses to interferon-alpha in chronic hepatitis C.  J. Infect. Dis.  1996;174;1  Link to Factors affecting treatment responses to interferon-alpha in chronic hepatitis C.
  161. CommentLetter Pawlotsky JM, Roudot-Thoraval F, Bastie A, Pellet C, Duval J, Dhumeaux D. Are hepatitis C virus genotypes 1a and 1b so different?  Hepatology  1996;23;5  Link to Are hepatitis C virus genotypes 1a and 1b so different?
  162. Journal ArticleReview Pawlotsky JM, Lunel F, Zarski JP, Laurent-Puig P, Bréchot C. [Biological diagnosis of hepatitis C virus infection. Role of serological and molecular tests]  Gastroenterol. Clin. Biol.  1996;20;2  Link to [Biological diagnosis of hepatitis C virus infection. Role of serological and molecular tests]
  163. Editorial Pawlotsky JM. [Chronic hepatitis C: therapeutic uncertainties. The virologist's point of view]  Gastroenterol. Clin. Biol.  1996;20;12  Link to [Chronic hepatitis C: therapeutic uncertainties. The virologist's point of view]
  164. Journal Article Serfaty L, Chazouillères O, Pawlotsky JM, Andreani T, Pellet C, Poupon R. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity.  Gastroenterology  1996;110;1  Link to Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity.

    165. 1995

  165. Letter Pawlotsky JM, Roudot-Thoraval F, Bastie A, Duval J, Dhumeaux D. Are basal core-IgM antibodies to hepatitis C virus predictive of successful alpha-interferon therapy?  J. Hepatol.  1995;23;6  Link to Are basal core-IgM antibodies to hepatitis C virus predictive of successful alpha-interferon therapy?
  166. Journal Article Pawlotsky JM, Bouvier M, Fromont P, Deforges L, Duval J, Dhumeaux D, Bierling P. Hepatitis C virus infection and autoimmune thrombocytopenic purpura.  J. Hepatol.  1995;23;6  Link to Hepatitis C virus infection and autoimmune thrombocytopenic purpura.
  167. Journal Article Pawlotsky JM, Darthuy F, Rémiré J, Pellet C, Udin L, Stuyver L, Roudot-Thoraval F, Duvoux C, Douvin C, Mallat A. Significance of anti-hepatitis C virus core IgM antibodies in patients with chronic hepatitis C.  J. Med. Virol.  1995;47;3  Link to Significance of anti-hepatitis C virus core IgM antibodies in patients with chronic hepatitis C.
  168. Journal Article Stuyver L, Wyseur A, van Arnhem W, Lunel F, Laurent-Puig P, Pawlotsky JM, Kleter B, Bassit L, Nkengasong J, van Doorn LJ. Hepatitis C virus genotyping by means of 5'-UR/core line probe assays and molecular analysis of untypeable samples.  Virus Res.  1995;38;2-3  Link to Hepatitis C virus genotyping by means of 5'-UR/core line probe assays and molecular analysis of untypeable samples.
  169. Journal Article Duvoux C, Pawlotsky JM, Cherqui D, Tran van Nhieu J, Metreau JM, Fagniez PL, Duval J, Zafrani ES, Dhumeaux D. Serial quantitative determination of hepatitis C virus RNA levels after liver transplantation. A useful test for diagnosis of hepatitis C virus reinfection.  Transplantation  1995;60;5  Link to Serial quantitative determination of hepatitis C virus RNA levels after liver transplantation. A useful test for diagnosis of hepatitis C virus reinfection.
  170. Journal Article Pawlotsky JM, Bélec L, Grésenguet G, Deforges L, Bouvier M, Duval J, Dhumeaux D. High prevalence of hepatitis B, C, and E markers in young sexually active adults from the Central African Republic.  J. Med. Virol.  1995;46;3  Link to High prevalence of hepatitis B, C, and E markers in young sexually active adults from the Central African Republic.
  171. Journal Article Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J, Dhumeaux D. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C.  J. Infect. Dis.  1995;171;6  Link to Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C.
  172. Letter Pawlotsky JM, Maisonneuve P, Duval J, Dhumeaux D, Noel L. Significance of NS5-"indeterminate" third-generation anti-hepatitis C virus serologic assays.  Transfusion  1995;35;5  Link to Significance of NS5-"indeterminate" third-generation anti-hepatitis C virus serologic assays.
  173. Journal Article Pawlotsky JM, Roudot-Thoraval F, Simmonds P, Mellor J, Ben Yahia MB, André C, Voisin MC, Intrator L, Zafrani ES, Duval J, Dhumeaux D. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes.  Ann. Intern. Med.  1995;122;3  Link to Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes.
  174. EditorialEnglish Abstract Pawlotsky JM, Dhumeaux D. [Treatment of chronic hepatitis C]  Presse Med  1995;24;3  Link to [Treatment of chronic hepatitis C]
  175. Journal Article Pawlotsky JM, Remire J, Darthuy F, Intrator L, Udin L, Dhumeaux D, Duval J. Is the detection of anti-hepatitis C virus core IgM influenced by the presence of serum rheumatoid factor?  J. Med. Virol.  1995;45;1  Link to Is the detection of anti-hepatitis C virus core IgM influenced by the presence of serum rheumatoid factor?

    176. 1994

  176. Journal Article Duvoux C, Pawlotsky JM, Cherqui D, Julien M, Duval J, Dhumeaux D. Diagnosis of HCV recurrence after liver transplantation using branched DNA assay for HCV RNA quantitation.  Transplantation  1994;58;8  Link to Diagnosis of HCV recurrence after liver transplantation using branched DNA assay for HCV RNA quantitation.
  177. Case ReportsLetter Pawlotsky JM, Abuaf N, Andre C, Deforges L, Duval J, Dhumeaux D. Serum anti-liver cytosol antibodies type 1 in hepatitis C virus infection.  J. Hepatol.  1994;21;3  Link to Serum anti-liver cytosol antibodies type 1 in hepatitis C virus infection.
  178. Clinical TrialComparative StudyControlled Clinical TrialJournal Article Lamoril J, Lunel F, Laurent-Puig P, Defer C, Loiseau P, Lefrère JJ, Pawlotsky JM, Marcellin P, Bouchardeau F, Bogard M. Indeterminate third-generation recombinant immunoblot assay in hepatitis C virus infection. Group d'Etudes Moléculaires des Hépatites (GEMHEP).  J. Hepatol.  1994;21;1  Link to Indeterminate third-generation recombinant immunoblot assay in hepatitis C virus infection. Group d'Etudes Moléculaires des Hépatites (GEMHEP).
  179. Journal Article Pawlotsky JM, Ben Yahia M, Andre C, Voisin MC, Intrator L, Roudot-Thoraval F, Deforges L, Duvoux C, Zafrani ES, Duval J. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study.  Hepatology  1994;19;4  Link to Immunological disorders in C virus chronic active hepatitis: a prospective case-control study.
  180. Journal ArticleReview Pawlotsky JM, Marcellin P, Trépo C, Dhumeaux D. [Treatment of viral hepatitis C]  Gastroenterol. Clin. Biol.  1994;18;4  Link to [Treatment of viral hepatitis C]
  181. Case ReportsLetter Pawlotsky JM, Bouvier M, Deforges L, Duval J, Bierling P, Dhumeaux D. Chronic hepatitis C after high-dose intravenous immunoglobulin.  Transfusion  1994;34;1  Link to Chronic hepatitis C after high-dose intravenous immunoglobulin.
  182. CommentLetter Pawlotsky JM, Roudot-Thoraval F, Duvoux C, Dhumeaux D, Babany G, Duval J. Virological and biochemical responses to interferon-alpha in chronic hepatitis C.  Lancet  1994;343;8888  Link to Virological and biochemical responses to interferon-alpha in chronic hepatitis C.

    183. 1993

  183. Journal Article Roudot-Thoraval F, Pawlotsky JM, Thiers V, Deforges L, Girollet PP, Guillot F, Huraux C, Aumont P, Brechot C, Dhumeaux D. Lack of mother-to-infant transmission of hepatitis C virus in human immunodeficiency virus-seronegative women: a prospective study with hepatitis C virus RNA testing.  Hepatology  1993;17;5  Link to Lack of mother-to-infant transmission of hepatitis C virus in human immunodeficiency virus-seronegative women: a prospective study with hepatitis C virus RNA testing.
  184. In VitroJournal Article Pawlotsky JM, Ruszniewski P, Reyl-Desmars F, Bourgeois M, Lewin MJ. Effects of PGE2, misoprostol, and enprostil on guinea pig enterocyte adenylate cyclase. Clinical implications.  Dig. Dis. Sci.  1993;38;2  Link to Effects of PGE2, misoprostol, and enprostil on guinea pig enterocyte adenylate cyclase. Clinical implications.
  185. Journal Article Pawlotsky JM, Deforges L, Bretagne S, André C, Métreau JM, Thiers V, Zafrani ES, Goossens M, Duval J, Mavier JP. Hepatitis C virus infection can mimic type 1 (antinuclear antibody positive) autoimmune chronic active hepatitis.  Gut  1993;34;2 Suppl  Link to Hepatitis C virus infection can mimic type 1 (antinuclear antibody positive) autoimmune chronic active hepatitis.
  186. Journal Article Roudot-Thoraval F, Pawlotsky JM, Deforges L, Girollet PP, Dhumeaux D. Anti-HCV seroprevalence in pregnant women in France.  Gut  1993;34;2 Suppl  Link to Anti-HCV seroprevalence in pregnant women in France.

    187. 1992

  187. Journal Article Pawlotsky JM, Andre C, Metreau JM, Beaugrand M, Zafrani ES, Dhumeaux D. Multiple nuclear dots antinuclear antibodies are not specific for primary biliary cirrhosis.  Hepatology  1992;16;1  Link to Multiple nuclear dots antinuclear antibodies are not specific for primary biliary cirrhosis.
  188. Journal Article Pawlotsky JM, Dhumeaux D. [Hepatitis B. Epidemiology, etiology, diagnosis, development, prognosis, principles of treatment]  Rev Prat  1992;42;5  Link to [Hepatitis B. Epidemiology, etiology, diagnosis, development, prognosis, principles of treatment]
Back to page of Pawlotsky, Jean-Michel.

Due mainly to homonyms, errors are possible and if you detect "false positives" or "false negatives" don't be too frustrated and please contact the webmaster.